ArticleFrontiers in immunology2022

Risk of HBV reactivation in relapsed or refractory diffuse large B-cell lymphoma patients receiving Bruton tyrosine kinase inhibitors therapy.

Ying Ni et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.